NCT00926965View on ClinicalTrials.gov

Tardive Dyskinesia and Cognitive Function

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Tardive DyskinesiaNeurocognitive Function
Interventions
DRUG

amisulpride

amisulpride tablet 100-1200mg/day for 24 months

DRUG

Olanzapine

Olanzapine tablet 2.5 to 30 mg/day for 24 months

DRUG

Conventional antipsychotics

the subjects were randomized to the conventional antipsychotic group to maintain their original conventional antipsychotics

Trial Locations (1)

981

Yu-Li Veternas Hospital, Hualien City

All Listed Sponsors
collaborator

National Science and Technology Council, Taiwan

OTHER_GOV

lead

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

NCT00926965 - Tardive Dyskinesia and Cognitive Function | Biotech Hunter | Biotech Hunter